Association of mutations with morphological dysplasia in *de novo* acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities

Olga K. Weinberg,[1] Christopher J. Gibson,[2] Traci M. Blonquist,[3] Donna Neuberg,[3] Olga Pozdnyakova,[4] Frank Kuo,[4] Benjamin L. Ebert[5] and Robert P. Hasserjian[5]

[1]Department of Pathology, Boston Children's Hospital; [2]Division of Hematology, Brigham and Women's Hospital, Dana Farber Cancer Institute; [3]Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute; [4]Department of Pathology, Brigham and Women's Hospital and [5]Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

Supplementary Table 1 Types of dysplastic changes in de novo AML and inter-rater agreement of specific dysplastic features scoring

	Median Observer Score							Kendall's W
	NE	0 (<10% cells)	1 (10-25% cells)	2 (26-50% cells)	3 (51-75% cells)	4 (>75% cells)		
Erythroid lineage								
Megaloblastic change in erythroid cells	29 (17.3%)	82 (48.8%)	12 (7.1%)	34 (20.2%)	11 (6.5%)	0 (0%)		0.72
Multi-nucleation in erythroid cells	29 (17.3%)	98 (58.3%)	4 (2.4%)	25 (14.9%)	11 (6.5%)	1 (0.6%)		0.746
Nuclear irregularities in erythroid cells	29 (17.3%)	28 (16.7%)	22 (13.1%)	59 (35.1%)	24 (14.3%)	6 (3.6%)		0.769
Myeloid lineage								
Abnormal nuclear shape in myeloid cells	23 (13.7%)	71 (42.3%)	18 (10.7%)	39 (23.2%)	16 (9.5%)	1 (0.6%)		0.71
Hypogranulation in myeloid cells	23 (13.7%)	59 (35.1%)	30 (17.9%)	28 (16.7%)	25 (14.9%)	3 (1.8%)		0.767
Megakaryocytes								
Micromegakaryocytes	36 (21.4%)	68 (40.5%)	10 (6.0%)	29 (17.3%)	19 (11.3%)	6 (3.6%)		0.744
Megakaryocytes with separated lobes	36 (21.4%)	63 (37.5%)	17 (10.1%)	23 (13.7%)	20 (11.9%)	9 (5.4%)		0.815
Megakaryocytes with Hypolobated nuclei	36 (21.4%)	41 (24.4%)	14 (8.3%)	59 (35.1%)	18 (10.7%)	0 (0%)		0.647